Rosuvastatin treatment for preventing contrast-induced acute kidney injury after cardiac catheterization: A meta-Analysis of randomized controlled trials

Medicine (United States)

Volumn 94, Issue 30, 2015, Pages

  Yang, You ^a   Wu, Yan Xian ^a   Hu, Yun Zhao ^a  

^a SHUNDE HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; ROSUVASTATIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; CREATININE CLEARANCE; GLOMERULUS FILTRATION RATE; HEART CATHETERIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; JADAD SCORE; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DIAGNOSTIC USE; INCIDENCE; PROCEDURES;

ACUTE KIDNEY INJURY; CARDIAC CATHETERIZATION; CARDIOVASCULAR DISEASES; CONTRAST MEDIA; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES;

EID: 84942422109     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001226     Document Type: Article

References (28)

1. Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI Registry. JACC Cardiovasc Interv. 2014; 7: 1-9.
2. Seeliger E, Sendeski M, Rihal CS, et al. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012; 33: 2007-2015.
3. Li Y, Liu Y, Fu L, et al. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-Analysis of seven randomized controlled trials. PLoS One. 2012; 7: e34450.
4. Liu Y, Liu YH, Tan N, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention. PLoS One. 2014; 9: e111124.
5. Han Y, Zhu G, Han L, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 2014; 63: 62-70.
6. Leoncini M, Toso A, Maioli M, et al. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol. 2014; 63: 71-79.
7. Abaci O, Arat OA, Kocas C, et al. Impact of Rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography. Am J Cardiol. 2015; 115: 867-871.
8. Stacul F, van der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011; 21: 2527-2541.
9. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1-12.
10. Verhagen AP, de Vet HC, de Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998; 51: 1235-1241.
11. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-Analyses. BMJ. 2003; 327: 557-560.
12. Oliveira MSD, Martins KBA, Costa JR Jr et al. Impact on renal function of rosuvastatin preload prior to elective percutaneous coronary intervention chronic statin users. Revista Brasileira de Cardiologia Invasiva. 2012; 20: 303-308.
13. Ahmed Abdul-Aziz ElTahawy, Basem Elsaid Enany, Mohsen Fahmy. Role of rosuvastatin pretreatment in prevention of contrast induced nephropathy in patients undergoing coronary angiography. Pak Heart J. 2013; 46: 250-254.
14. Aurelio A, Durante A. Contrast-induced nephropathy in percutaneous coronary interventions: pathogenesis, risk factors, outcome, prevention and treatment. Cardiology. 2014; 128: 62-72.
15. Wassmann S, Faul A, Hennen B, et al. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res. 2003; 93: e98-e103.
16. Ongini E, Impagnatiello F, Bonazzi A, et al. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Natl Acad Sci U S A. 2004; 101: 8497-8502.
17. Toth PP. An update on the benefits and risks of rosuvastatin therapy. Postgrad Med. 2014; 126: 7-17.
18. Ferreira TS, Lanzetti M, Barroso MV, et al. Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke. Inflammation. 2014; 37: 1355-1365.
19. Vidt DG, Harris S, McTaggart F, et al. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol. 2006; 97: 1602-1606.
20. Agarwal R. Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol. 2004; 15: 2502-2503.
21. Takagi H, Umemoto T. A meta-Analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles. Am J Cardiol. 2014; 113: 292-301.
22. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipidmodifying therapy. J Intern Med. 2004; 255: 188-205.
23. Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-An Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010; 55: 1266-1273.
24. Fox ER, Benjamin EJ, Sarpong DF, et al. The relation of C-reactive protein to chronic kidney disease in African Americans: the Jackson Heart Study. BMC Nephrol. 2010; 11: 1-7.
25. Patti G, Ricottini E, Nusca A, et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrastinduced nephropathy trial]). Am J Cardiol. 2011; 108: 1-7.
26. Yun KH, Lim JH, Hwang KB, et al. Effect of high dose rosuvastatin loading before percutaneous coronary intervention on contrastinduced nephropathy. Korean Circ J. 2014; 44: 301-306.
27. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2015; 10: 1024-1094.
28. Toso A, Leoncini M, Maioli M, et al. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention). JACC Cardiovasc Interv. 2014; 7: 1421-1429.